GoConqr hat ein neues Design! Sag uns, wie es dir gefällt.

Kostenlos registrieren

Karteikarten

Medchem 1 Final

Camille Bassil Pharmacy Englisch 5,0Durchschnittliche Bewertung 5,0 von 5 (1 Bewertung) 167 Karten

Medchem 1 Final

Karten in diesem Stapel (167)

  1. 1—amobarbital
    (barbituric acid derivatives)    amobarbital (barbituric acid derivatives)
  2. 2—barbituric acidbarbituric acid
  3. 3—butabarbital
    (barbituric acid derivatives)    butabarbital (barbituric acid derivatives)
  4. 4—butalital
    (barbituric acid derivatives)    butalital (barbituric acid derivatives)
  5. 5—dilactimdilactim
  6. 6—hexahydropyrimidine 2,4,6-trionehexahydropyrimidine 2,4,6-trione
  7. 7—hexahydropyrimidinehexahydropyrimidine
  8. 8—mephobarbital
    (barbituric acid derivatives)
    SHORT doa RAPID ONSET    mephobarbital (barbituric acid derivatives) SHORT doa RAPID ONSET
  9. 9—methohexital
    (barbituric acid derivatives)    methohexital (barbituric acid derivatives)
  10. 10—monolactimmonolactim
  11. 11—pentobarbital
    (barbituric acid derivatives)    pentobarbital (barbituric acid derivatives)
  12. 12—phenobarbital
    (barbituric acid derivatives)    phenobarbital (barbituric acid derivatives)
  13. 13—pyrimidinepyrimidine
  14. 14—secobarbital
    (barbituric acid derivatives)    secobarbital (barbituric acid derivatives)
  15. 15—thiopental
    (barbituric acid derivatives)    thiopental (barbituric acid derivatives)
  16. 16—butabarbital
    (barbituric acid derivatives)    butabarbital (barbituric acid derivatives)
  17. 17—butathal
    (barbituric acid derivatives)    butathal (barbituric acid derivatives)
  18. 18—chloral hydrate
    (non barbiturates)
    aldehydes useful for insomnia
    not analgesic
    initial acitivity    chloral hydrate (non barbiturates) aldehydes useful for insomnia not analgesic initial acitivity
  19. 19—chloral
    (non barbiturates)    chloral (non barbiturates)
  20. 20—cyclobarbital
    (barbituric acid derivatives)    cyclobarbital (barbituric acid derivatives)
  21. 21—diphenhydramine
    (antihistamine)
    cross BBB
    cause CNS effects    diphenhydramine (antihistamine) cross BBB cause CNS effects
  22. 22—doxylamine
    (antihistamines)    doxylamine (antihistamines)
  23. 23—hexethal
    (barbituric acid derivatives)    hexethal (barbituric acid derivatives)
  24. 24—indeno (5,6b) furan
    (modified melatonin receptor agonist)    indeno (5,6b) furan (modified melatonin receptor agonist)
  25. 25—mephobarbital
    (barbituric acid derivatives)    mephobarbital (barbituric acid derivatives)
  26. 26—phenobarbital
    (barbituric acid derivatives)    phenobarbital (barbituric acid derivatives)
  27. 27—phenobarbital
    (barbituric acid derivatives)    phenobarbital (barbituric acid derivatives)
  28. 28—ramelteon
    indeno (5,4b) furan
    (modified melatonin receptor agonist)
    higher affinity to MT1 receptor    ramelteon indeno (5,4b) furan (modified melatonin receptor agonist) higher affinity to MT1 receptor
  29. 29—ramelteon
    (modified melatonin receptor agonist)    ramelteon (modified melatonin receptor agonist)
  30. 30—trichloroethanol
    (non barbiturate)    trichloroethanol (non barbiturate)
  31. 31—tricholoroacetic acid
    (non barbiturate)    tricholoroacetic acid (non barbiturate)
  32. 32—alprazolam (xanax)alprazolam (xanax)
  33. 33—clorazepate (tranxene)
    only BZD prodrug    clorazepate (tranxene) only BZD prodrug
  34. 34—diazepam (valium)
    long DOA
    Diazepam is metabolized to: Nordiazepam Temazepam oxazepam
    All metabolites are active    diazepam (valium) long DOA Diazepam is metabolized to: Nordiazepam Temazepam oxazepam All metabolites are active
  35. 35—estazolam
    sleep inducer in elderly
    onset of activity: 30min    estazolam sleep inducer in elderly onset of activity: 30min
  36. 36—eszopiclone
    cyclopyrrolone
    orally active
    well absorbed
    t 1/2: 6h
    •“S” isomer of zopiclone
    •Longer t ½ around 6hrs    eszopiclone cyclopyrrolone orally active well absorbed t 1/2: 6h •“S” isomer of zopiclone •Longer t ½ around 6hrs
  37. 37—flurazepam (dalmane)
    sleep inducer
    short half life: 2.4h
    very long DOA
    onset of activity: 30min
    The t ½ of flurazepam is 2.4hrs, metabolized into hydroxyethylflurazepam
    and N-desalkylflurazepam, both are active with t ½ of 3-4hrs and 47-100hrs, respectively.    flurazepam (dalmane) sleep inducer short half life: 2.4h very long DOA onset of activity: 30min The t ½ of flurazepam is 2.4hrs, metaboli...
  38. 38—halazepam (paxipam)halazepam (paxipam)
  39. 39—hydroxyethylflurazepam
    active
    long DOA
    half life: 3-4h    hydroxyethylflurazepam active long DOA half life: 3-4h
  40. 40—metabolite of estazolam
    active
    short acting    metabolite of estazolam active short acting
  41. 41—metabolite of triazolam
    active
    short acting    metabolite of triazolam active short acting
  42. 42—midazolam (versed)midazolam (versed)
  43. 43—n-desalkylflurazepam
    active
    long DOA
    half life: 47-100h    n-desalkylflurazepam active long DOA half life: 47-100h
  44. 44—oxazepam (serax)oxazepam (serax)
  45. 45—temazepam (restoril)
    sleep inducer
    onset of activity:1-2h
    Temazepam is rapidly metabolized via direct conjugation with glucuronic acid    temazepam (restoril) sleep inducer onset of activity:1-2h Temazepam is rapidly metabolized via direct conjugation with glucuronic acid
  46. 46—triazolam (halcion)
    sleep inducer in elderly
    onset of activity:1-2h    triazolam (halcion) sleep inducer in elderly onset of activity:1-2h
  47. 47—zaleplon
    pyrazolopyrimidine
    orally active
    rapidly absorbed
    low bioavailabity: 30%
    t 1/2: 1hImidazopyridine
    food delays its effect
    all metabolites are inactive    zaleplon pyrazolopyrimidine orally active rapidly absorbed low bioavailabity: 30% t 1/2: 1hImidazopyridine food delays its effect all met...
  48. 48—zopidem
    imidazopyridine
    orally active
    rapid onset: 1.4 h
    short acting
    t 1/2: 2h
    Food delays its effects
    •Short acting due to rapid oxidative metabolism into inactive metabolites
    highly bound to plasma proteins    zopidem imidazopyridine orally active rapid onset: 1.4 h short acting t 1/2: 2h Food delays its effects •Short acting due to rapid oxidat...
  49. 49—(+-) - nisoxetine
    non TCA secondary amines
    SNRI (NE)    (+-) - nisoxetine non TCA secondary amines SNRI (NE)
  50. 50—amoxapine
    non typical TCA secondary amine
    SNRI    amoxapine non typical TCA secondary amine SNRI
  51. 51—clorgyline
    MAOI (selective A)
    hypertensive crisis with tyramine    clorgyline MAOI (selective A) hypertensive crisis with tyramine
  52. 52—desipramine
    10,11-dihydrodibenzazepine ring
    secondary amine orally active TCA
    SNRI
    block muscarinic, alpha 1, H1 , Na channel
    CI with MAOI and TCA and SNRI => HYPERTENSION
    metabolized by CYP ( n desmethyl or hydroxylation
    Aadditive anticholinergic and sympathomimetic
    Na channel inhibitors : slow ventricular conduction at therapeutic dose    desipramine 10,11-dihydrodibenzazepine ring secondary amine orally active TCA SNRI block muscarinic, alpha 1, H1 , Na channel CI with MAO...
  53. 53—iproniazid
    MAOI (non selective)
    hydrazine
    hypertensive crisis with tyramine    iproniazid MAOI (non selective) hydrazine hypertensive crisis with tyramine
  54. 54—isoniazid
    antituberculosis
    MAOI    isoniazid antituberculosis MAOI
  55. 55—maprotiline
    TCA tetracyclic (bicyclic ring)
    SNRI
    block muscarinic, alpha 1, H1 , Na channel
    CI with MAOI and TCA and SNRI => HYPERTENSION
    metabolized by CYP ( n desmethyl or hydroxylation
    Aadditive anticholinergic and sympathomimetic
    Na channel inhibitors : slow ventricular conduction at therapeutic dose    maprotiline TCA tetracyclic (bicyclic ring) SNRI block muscarinic, alpha 1, H1 , Na channel CI with MAOI and TCA and SNRI => HYPERTENS...
  56. 56—moclobemide
    MAOI (selective A)
    hypertensive crisis with tyramine    moclobemide MAOI (selective A) hypertensive crisis with tyramine
  57. 57—nortriptyline
    10,11-Dibenzocyclohepten-5-
    orally active TCA
    SNRIblock muscarinic, alpha 1, H1 , Na channel
    CI with MAOI and TCA and SNRI => HYPERTENSION
    metabolized by CYP ( n desmethyl or hydroxylation
    Aadditive anticholinergic and sympathomimetic
    Na channel inhibitors : slow ventricular conduction at therapeutic dose    nortriptyline 10,11-Dibenzocyclohepten-5- orally active TCA SNRIblock muscarinic, alpha 1, H1 , Na channel CI with MAOI and TCA and SNRI ...
  58. 58—phenelzine
    MAOI (non selective)
    hydrazine
    hypertensive crisis with tyramine    phenelzine MAOI (non selective) hydrazine hypertensive crisis with tyramine
  59. 59—protriptyline
    dibenzocycloheptene ring
    orally active TCA
    SNRI
    block muscarinic, alpha 1, H1 , Na channel
    CI with MAOI and TCA and SNRI => HYPERTENSION
    metabolized by CYP ( n desmethyl or hydroxylation
    Aadditive anticholinergic and sympathomimetic
    Na channel inhibitors : slow ventricular conduction at therapeutic dose    protriptyline dibenzocycloheptene ring orally active TCA SNRI block muscarinic, alpha 1, H1 , Na channel CI with MAOI and TCA and SNRI =&...
  60. 60—R(-) - atomoxetine
    non TCA
    SNRI    R(-) - atomoxetine non TCA SNRI
  61. 61—S,S- reboxetine
    non TCA
    SNRI    S,S- reboxetine non TCA SNRI
  62. 62—selegiline
    MAOI (selective B)    selegiline MAOI (selective B)
  63. 63—tranylcypromine
    MAOI (non selective)
    non hydrazine
    hypertensive crisis with tyramine    tranylcypromine MAOI (non selective) non hydrazine hypertensive crisis with tyramine
  64. 64—(-) 3S,4R- paroxetine
    2 chiral center with 4 possible stereoisomer
    3S,4R (-) PAROXETINE
    Phenoxyphenylalkylamines
    piperidine ring
    SSRI
    non TCA
    potent and selective SERT little affinity for NET
    orally active
    metabolized by CYP2d6 into inactive catechol than methyl or glucuronide    (-) 3S,4R- paroxetine 2 chiral center with 4 possible stereoisomer 3S,4R (-) PAROXETINE Phenoxyphenylalkylamines piperidine ring SSRI non...
  65. 65—(+-)- talopram
    Phenoxyphenylalkylamines
    SSRI
    non TCA    (+-)- talopram Phenoxyphenylalkylamines SSRI non TCA
  66. 66—(+-)- venlafaxine
    NSRI
    non TCA
    methoxyphenylethylamine
    metabolized into equipotent O-desmethyl venlafaxine
    30x more potent for SERT than NET    (+-)- venlafaxine NSRI non TCA methoxyphenylethylamine metabolized into equipotent O-desmethyl venlafaxine 30x more potent for SERT than NET
  67. 67—(+-)-cis-milnacipran
    NSRI
    non TCA
    Phenylcyclopropanecarboxamide
    antidepressant similar to TCA and SSRI
    safe    (+-)-cis-milnacipran NSRI non TCA Phenylcyclopropanecarboxamide antidepressant similar to TCA and SSRI safe
  68. 68—1S,4S-N-desmethylsertraline
    Phenylalkylamine derivatives
    SSRI
    active
    t 1/2=60-104h    1S,4S-N-desmethylsertraline Phenylalkylamine derivatives SSRI active t 1/2=60-104h
  69. 69—1S,4S-sertraline (zoloft)
    Phenylalkylamine derivatives
    SSRI
    potent
    2 chiral centers
    t 1/2=26h
    active metabolite n desmethyl
    weak inhibitor of CYP3A4    1S,4S-sertraline (zoloft) Phenylalkylamine derivatives SSRI potent 2 chiral centers t 1/2=26h active metabolite n desmethyl weak inhibito...
  70. 70—amitriptyline
    NSRI
    TCA tertiary amine selective to serotonin as compared to 2ary
    greater anticholinergic, antihistaminic, antiadrenergic
    potent inhibitors of sodium channels increased cardiotoxicity and higher frequency of seizures
    SEROTONIN syndrome in DDI    amitriptyline NSRI TCA tertiary amine selective to serotonin as compared to 2ary greater anticholinergic, antihistaminic, antiadrenergic ...
  71. 71—clomipramine
    NSRI
    Dihydrodibenzazepine
    TCA
    most powerful antidepressant
    desmethyl active    clomipramine NSRI Dihydrodibenzazepine TCA most powerful antidepressant desmethyl active
  72. 72—doxepin (E-isomer)
    NSRI
    dibenzoxepine derivative
    less active
    Z ISOMER > E
    n desmethyl active    doxepin (E-isomer) NSRI dibenzoxepine derivative less active Z ISOMER > E n desmethyl active
  73. 73—doxepin (Z-isomer)
    NSRI
    dibenzoxepine derivative
    more active    doxepin (Z-isomer) NSRI dibenzoxepine derivative more active
  74. 74—imipramine
    NSRI
    TCA tertiary amine selective to serotonin as compared to 2ary
    greater anticholinergic, antihistaminic, antiadrenergic
    potent inhibitors of sodium channels increased cardiotoxicity and higher frequency of seizures
    SEROTONIN syndrome in DDI    imipramine NSRI TCA tertiary amine selective to serotonin as compared to 2ary greater anticholinergic, antihistaminic, antiadrenergic pot...
  75. 75—S (+)- duloxetine
    NSRI
    non TCA
    fluoxetine analogue
    SERT > NET
    CYP2D6 Ndesmethyl active
    CYP3A4 4 hydroxyl active with sert>net    S (+)- duloxetine NSRI non TCA fluoxetine analogue SERT > NET CYP2D6 Ndesmethyl active CYP3A4 4 hydroxyl active with sert>net
  76. 76—S- talsupram
    Phenoxyphenylalkylamines
    isobenzothiophene
    potent
    NET INHIBITOR
    active    S- talsupram Phenoxyphenylalkylamines isobenzothiophene potent NET INHIBITOR active
  77. 77—S-citalopram
    Phenoxyphenylalkylamines
    isobenzofuran
    SSRI
    orally active
    N DESMETHYL ACTIVE
    S enantiomer 27 X more potent    S-citalopram Phenoxyphenylalkylamines isobenzofuran SSRI orally active N DESMETHYL ACTIVE S enantiomer 27 X more potent
  78. 78—S-fluoxetine (prozac)
    Phenoxyphenylalkylamines
    3-phenoxy-3phenylpropylamine
    SSRI
    S isomer more potent (2x) than R
    orally active    S-fluoxetine (prozac) Phenoxyphenylalkylamines 3-phenoxy-3phenylpropylamine SSRI S isomer more potent (2x) than R orally active
  79. 79—S-norfluoxetine
    Phenoxyphenylalkylamines
    SSRI
    S isomer more potent (7x) than R    S-norfluoxetine Phenoxyphenylalkylamines SSRI S isomer more potent (7x) than R
  80. 80—tametraline
    Phenylalkylamine derivatives
    SSRI    tametraline Phenylalkylamine derivatives SSRI
  81. 81—trimipramine
    NSRI
    dihydrodibenzazepine TCA
    low affinity by 100 to both transporters
    desmethyl is active    trimipramine NSRI dihydrodibenzazepine TCA low affinity by 100 to both transporters desmethyl is active
  82. 82—articaine
    local anesthetic
    amino amides    articaine local anesthetic amino amides
  83. 83—atropine
    local anesthetic
    low activity
    toxic/eye irritation    atropine local anesthetic low activity toxic/eye irritation
  84. 84—batracotoxin
    local anesthetic
    alkaloid
    from skin of poison arrow frog
    extremely toxic/not used    batracotoxin local anesthetic alkaloid from skin of poison arrow frog extremely toxic/not used
  85. 85—benoxinate
    local anesthetic
    amino ester    benoxinate local anesthetic amino ester
  86. 86—benzocaine
    local anesthetic
    amino ester
    tongue numbness
    poor water solubility    benzocaine local anesthetic amino ester tongue numbness poor water solubility
  87. 87—benzoyltropine
    local anesthetic
    decarbomethoxy derivative
    potent
    no addiction
    tissue irritation    benzoyltropine local anesthetic decarbomethoxy derivative potent no addiction tissue irritation
  88. 88—benzyl alcohol
    local anesthetic
    alcohol    benzyl alcohol local anesthetic alcohol
  89. 89—Bupivacaine
    local anesthetic
    amino amides
    long acting    Bupivacaine local anesthetic amino amides long acting
  90. 90—Butamben
    local anesthetic
    amino ester    Butamben local anesthetic amino ester
  91. 91—chloroprocaine
    local anesthetic
    amino ester    chloroprocaine local anesthetic amino ester
  92. 92—cocaine
    local anesthetic
    addictive
    toxic
    unstable
    allergic    cocaine local anesthetic addictive toxic unstable allergic
  93. 93—dibucaine
    local anesthetic
    amino amides    dibucaine local anesthetic amino amides
  94. 94—dyclonine
    local anesthetic
    amino ketone    dyclonine local anesthetic amino ketone
  95. 95—etidocaine
    local anesthetic
    amino amides
    long acting    etidocaine local anesthetic amino amides long acting
  96. 96—eugenol
    local anesthetic
    phenol    eugenol local anesthetic phenol
  97. 97—glycinexylidide
    metabolite of lidocaine
    active
    toxic (CNS side effect)    glycinexylidide metabolite of lidocaine active toxic (CNS side effect)
  98. 98—homatropine
    weak local anesthetic
    more active
    less irritating    homatropine weak local anesthetic more active less irritating
  99. 99—isogramine
    local anesthetic
    amide type
    indole
    tongue numbness    isogramine local anesthetic amide type indole tongue numbness
  100. 100—Levobupivacaine
    local anesthetic
    amino amides    Levobupivacaine local anesthetic amino amides
  101. 101—lidocaine
    local anesthetic
    amide type
    non irritating
    stable
    less allergic
    potent    lidocaine local anesthetic amide type non irritating stable less allergic potent
  102. 102—menthol
    local anesthetic
    alcohol    menthol local anesthetic alcohol
  103. 103—mepivacaine
    local anesthetic
    amino amides    mepivacaine local anesthetic amino amides
  104. 104—monoethylglycinexylidide
    metabolite of lidocaine
    active
    toxic (CNS side effect)    monoethylglycinexylidide metabolite of lidocaine active toxic (CNS side effect)
  105. 105—phenol
    local anesthetic    phenol local anesthetic
  106. 106—pramoxine
    local anesthetic
    amino ether    pramoxine local anesthetic amino ether
  107. 107—prilocaine
    local anesthetic
    amino amides    prilocaine local anesthetic amino amides
  108. 108—procaine
    local anesthetic
    N,N-diethyaminoethyl ester
    water soluble
    less potent
    safe
    short acting
    stable at low pH    procaine local anesthetic N,N-diethyaminoethyl ester water soluble less potent safe short acting stable at low pH
  109. 109—proparacaine
    local anesthetic
    amino ester    proparacaine local anesthetic amino ester
  110. 110—Propoxycaine
    local anesthetic
    amino ester    Propoxycaine local anesthetic amino ester
  111. 111—Ropivacaine
    local anesthetic
    amino amides    Ropivacaine local anesthetic amino amides
  112. 112—saxitoxin STX
    local anesthetic
    alkaloid
    marine neurotoxin from ovaries of puffer fish
    clam poison
    extremely toxic/not used    saxitoxin STX local anesthetic alkaloid marine neurotoxin from ovaries of puffer fish clam poison extremely toxic/not used
  113. 113—tetracaine
    local anesthetic
    n-butylamino derivative
    high lipophilicity
    most potent (50x)
    long acting    tetracaine local anesthetic n-butylamino derivative high lipophilicity most potent (50x) long acting
  114. 114—tetrodotoxin TTX (hemiacetal form)
    local anesthetic
    alkaloid
    marine neurotoxin from ovaries of puffer fish
    extremely toxic/not used    tetrodotoxin TTX (hemiacetal form) local anesthetic alkaloid marine neurotoxin from ovaries of puffer fish extremely toxic/not used
  115. 115—tetrodotoxin TTX (lactone form)
    local anesthetic
    alkaloid
    marine neurotoxin from ovaries of puffer fish
    extremely toxic/not used    tetrodotoxin TTX (lactone form) local anesthetic alkaloid marine neurotoxin from ovaries of puffer fish extremely toxic/not used
  116. 116—tocainide
    lidocaine analogue
    no CNS side effect    tocainide lidocaine analogue no CNS side effect
  117. 117—tolycaine
    lidocaine analogue
    no CNS side effect    tolycaine lidocaine analogue no CNS side effect
  118. 118—cyclopropane
    volatile general anesthetic    cyclopropane volatile general anesthetic
  119. 119—desflurane
    volatile general anesthetic
    potent
    rapid induction/ recovery (outpatient)
    no hepatotoxicity/ nephrotoxicity
    non corrosive to metals( stable)
    PUNGENT volatile    desflurane volatile general anesthetic potent rapid induction/ recovery (outpatient) no hepatotoxicity/ nephrotoxicity non corrosive to m...
  120. 120—diethyl ehter
    volatile general anesthetic
    high potency
    analgesic
    Neuromuscular relaxing effects
    flammable
    slow induction/recovery    diethyl ehter volatile general anesthetic high potency analgesic Neuromuscular relaxing effects flammable slow induction/recovery
  121. 121—enflurane
    volatile general anesthetic
    high potency
    high dose: convulsion and circulatory depression
    give F- and fluoromethoxy difluro acetic acid    enflurane volatile general anesthetic high potency high dose: convulsion and circulatory depression give F- and fluoromethoxy difluro ace...
  122. 122—halothane
    volatile general anesthetic
    potent
    sweet odor agent of choice in children
    rapid onset/recovery
    give HCL HBr
    HEPATOTOXICITY    halothane volatile general anesthetic potent sweet odor agent of choice in children rapid onset/recovery give HCL HBr HEPATOTOXICITY
  123. 123—isoflurane
    volatile general anesthetic
    pungent odor given IV fewer cardiovascular effects
    give F- and CF3COOH
    potent    isoflurane volatile general anesthetic pungent odor given IV fewer cardiovascular effects give F- and CF3COOH potent
  124. 124—ketamine hydrochloride
    IV general anesthetic
    very potent
    slow onset
    short DOA
    no muscle relaxation
    produce hallucination dissociative anesthesia
    norketamine in liver
    blocks NMDA receptor
    increase BP AND HR    ketamine hydrochloride IV general anesthetic very potent slow onset short DOA no muscle relaxation produce hallucination dissociative ane...
  125. 125—methoxyflurane
    volatile general anesthetic
    most potent
    highest solubility in blood slow inducto and recovery
    chemically unstable
    NEPHROTOXICITY    methoxyflurane volatile general anesthetic most potent highest solubility in blood slow inducto and recovery chemically unstable NEPHROTO...
  126. 126—nitrous oxide
    volatile general anesthetic
    least potent
    adjunct therapy
    colorless tasteless odorless
    irreversible oxidation of Co atom in VitB12
    inactivation of enzymes
    methionine synthetase (myeline)
    thymidilate synthetase ( thymidine)    nitrous oxide volatile general anesthetic least potent adjunct therapy colorless tasteless odorless irreversible oxidation of Co atom in ...
  127. 127—propofol
    IV general anesthetic
    rapid induction and recovery
    increase GABA ergic neurotransmission within the CNS
    poor water soluble (soybean)
    glucuronude abd sulfate conjugayte
    outpatient (rapid induction/recovery
    vomiting )    propofol IV general anesthetic rapid induction and recovery increase GABA ergic neurotransmission within the CNS poor water soluble (soyb...
  128. 128—R-etomidate
    IV general anesthetic
    Ester of carboxylated imidazole
    potent
    solubilized in 35% Propylene Glycol
    rapid/short acting
    lacks analgesia
    hydrolyzed by esterase
    SEIZURES    R-etomidate IV general anesthetic Ester of carboxylated imidazole potent solubilized in 35% Propylene Glycol rapid/short acting lacks ana...
  129. 129—sevoflurane
    volatile general anesthetic
    higher potency than desflurane
    low blood solubility rapid induction and recovery
    low pungency
    metabolized to hexafluoro isopropanol
    low hepato and nephrotoxicity    sevoflurane volatile general anesthetic higher potency than desflurane low blood solubility rapid induction and recovery low pungency met...
  130. 130—thiopental
    IV general anesthetic
    rapid and pleasant induction
    short DOA
    enhance GABA ergic effect    thiopental IV general anesthetic rapid and pleasant induction short DOA enhance GABA ergic effect
  131. 131—phenothiazine
    typical neuroleptic    phenothiazine typical neuroleptic
  132. 132—phenothiazine
    typical neuroleptic    phenothiazine typical neuroleptic
  133. 133—piperazine moiety
    highest potency    piperazine moiety highest potency
  134. 134—piperidine moietypiperidine moiety
  135. 135—pyrolidine moietypyrolidine moiety
  136. 136—thiothixene
    thioxanthene typical antipsychotic
    synthetic
    cis > trans
    double bond reduction reduce activity    thiothixene thioxanthene typical antipsychotic synthetic cis > trans double bond reduction reduce activity
  137. 137—fluphenazine decanoate
    phenothiazine typical neuroleptic
    prodrug
    long acting
    IM    fluphenazine decanoate phenothiazine typical neuroleptic prodrug long acting IM
  138. 138—fluphenazine enanthate
    phenothiazine typical neuroleptic
    prodrug
    long acting
    IM    fluphenazine enanthate phenothiazine typical neuroleptic prodrug long acting IM
  139. 139—fluphenazine
    phenothiazine typical neuroleptic
    most potent    fluphenazine phenothiazine typical neuroleptic most potent
  140. 140—perphenazine enanthate
    phenothiazine typical neuroleptic
    pro drug    perphenazine enanthate phenothiazine typical neuroleptic pro drug
  141. 141—flupenthixol decanoate
    thioxanthene typical neuroleptic
    pro drug    flupenthixol decanoate thioxanthene typical neuroleptic pro drug
  142. 142—meperidine
    metabolite of butyrophenone
    typical neuroleptic
    analgesic    meperidine metabolite of butyrophenone typical neuroleptic analgesic
  143. 143—propophenone
    metabolite of butyrophenone
    typical neuroleptic
    (200x) more potent than meperidine as analgesic    propophenone metabolite of butyrophenone typical neuroleptic (200x) more potent than meperidine as analgesic
  144. 144—butyrophenone
    typical neuroleptic
    analgesic    butyrophenone typical neuroleptic analgesic
  145. 145—haloperidol (haldol)
    prototype butyrophenone
    typical neuroleptic    haloperidol (haldol) prototype butyrophenone typical neuroleptic
  146. 146—droperidol
    analogous of haloperidol
    typical neuroleptic
    short acting
    antiemetic    droperidol analogous of haloperidol typical neuroleptic short acting antiemetic
  147. 147—haloperidol decanoate
    analogues of haloperidol
    typical neuroleptic    haloperidol decanoate analogues of haloperidol typical neuroleptic
  148. 148—Spiperone
    analogues of haloperidol
    typical neuroleptic    Spiperone analogues of haloperidol typical neuroleptic
  149. 149—trifluperidol
    analogues of haloperidol
    typical neuroleptic    trifluperidol analogues of haloperidol typical neuroleptic
  150. 150—primozide
    diphenylbutylpiperidine
    long DOA
    against schizophrenia
    against tourette's syndrome    primozide diphenylbutylpiperidine long DOA against schizophrenia against tourette's syndrome
  151. 151—penfluridol
    diphenylbutylpiperidine
    long DOA
    typical neuroleptic
    against schizophrenia    penfluridol diphenylbutylpiperidine long DOA typical neuroleptic against schizophrenia
  152. 152—fluspirilene
    diphenylbutylpiperidine
    long DOA
    typical neuroleptic
    against schizophrenia    fluspirilene diphenylbutylpiperidine long DOA typical neuroleptic against schizophrenia
  153. 153—metoclopramide
    benzamide derivative
    atypical neuroleptic
    antiemetic
    local anesthetic activity    metoclopramide benzamide derivative atypical neuroleptic antiemetic local anesthetic activity
  154. 154—S(-)-Sulpiride
    benzamide derivative
    atypical neuroleptic
    metoclopramide pyrrolidine ring derivative
    low EPS
    hydrophilic (poor oral absorption,low CNS--> low potency)    S(-)-Sulpiride benzamide derivative atypical neuroleptic metoclopramide pyrrolidine ring derivative low EPS hydrophilic (poor oral absorp...
  155. 155—S(-)-remoxipride
    benzamide derivative
    atypical neuroleptic
    metoclopramide pyrrolidine ring derivative
    potent
    low EPS/autonomic side effect
    APLASTIC ANEMIA    S(-)-remoxipride benzamide derivative atypical neuroleptic metoclopramide pyrrolidine ring derivative potent low EPS/autonomic side effec...
  156. 156—Amisulpride
    benzamide
    atypical neuroleptic    Amisulpride benzamide atypical neuroleptic
  157. 157—clozapine (clozaril)
    benzazepine
    dibenzodiazepine derivative
    atypical neuroleptic
    low EPS
    orally active orally active and metabolized mainly by CYP3A4 to inactive desmethyl, hydroxyl, and N-oxide derivatives, with a half-life of approximately 12 hours.
    t1/2= 12h
    fatal agranulocytosis    clozapine (clozaril) benzazepine dibenzodiazepine derivative atypical neuroleptic low EPS orally active orally active and metabolized mai...
  158. 158—olanzapine (zyprexa)
    benzazepine
    thienobenzodiazepine derivative
    atypical neuroleptic
    potent
    high EPS
    orally absorbed
    Olanzepine is well absorbed after oral administration and is metabolized mainly by CYPIA2 to inactive metabolites, with a variable half-life of approximately 20 to 50 hours.
    t1/2= 20-50h    olanzapine (zyprexa) benzazepine thienobenzodiazepine derivative atypical neuroleptic potent high EPS orally absorbed Olanzepine is well ...
  159. 159—quetiapine (seroquel)
    benzazepine
    dibenzothiazepine derivative
    atypical neuroleptic
    100% bioavailable (orally active)
    first pass metabolism
    t1/2= 6hQuetiapine is 100% bioavailability
    first-pass metabolism yields at least 20 metabolites via CYP3A4
    7-hydroxyl and N-desalkylquetapine are active metabolites    quetiapine (seroquel) benzazepine dibenzothiazepine derivative atypical neuroleptic 100% bioavailable (orally active) first pass metaboli...
  160. 160—loxapine
    benzazepine
    dibenzo-oxazepine derivative
    atypical neuroleptic
    more typical profile
    undergoes aromatic hydroxylation to yield several phenolic metabolites that have higher affinity for D2 receptors than the parent.
    undergoes N-demethylation to form amoxapine, which is used clinically as an antidepressant.    loxapine benzazepine dibenzo-oxazepine derivative atypical neuroleptic more typical profile undergoes aromatic hydroxylation to yield sev...
  161. 161—amoxapine
    benzazepine
    dibenzo-oxazepine derivative
    n-demethylation of loxapine
    antidepressant    amoxapine benzazepine dibenzo-oxazepine derivative n-demethylation of loxapine antidepressant
  162. 162—risperidone
    benzizoxazole derivative
    atypical neuroleptic
    potent
    some EPS
    decrease schizophrenia
    orally absorbed
    give active metabolites
    undergoes hepatic CYP2D6 catalyzed 9-hydroxylation (active metabolite) and N-dealkylation.
    The half-life of risperidone and hydroxyrisperidone is about 22 hours
    t1/2= 22h    risperidone benzizoxazole derivative atypical neuroleptic potent some EPS decrease schizophrenia orally absorbed give active metabolites ...
  163. 163—Ziprasidone
    benzisothiazole derivative
    atypical neuroleptic
    potent
    orally active (60% bioavailable)
    t1/2= 6h
    extremely metabolizedorally active with 60% bioavailability
    t ½ is about 6 hours (increased by food)
    metabolized by aldehyde oxidase, which results in reductive cleavage of the S-N bond, and then by S-methylation.
    •Ziprasidone also can undergo N-dealkylation and S-oxidation by CYP3A4catalyzed    Ziprasidone benzisothiazole derivative atypical neuroleptic potent orally active (60% bioavailable) t1/2= 6h extremely metabolizedorally ...
  164. 164—Tiospirone
    benzisothiazole derivative
    atypical neuroleptic    Tiospirone benzisothiazole derivative atypical neuroleptic
  165. 165—aripiprazole
    arylpiperazine quinolinone derivative
    atypical neuroleptic
    low EPS/low hyperprolactinemia
    partial agonist activity at some D2 receptors    aripiprazole arylpiperazine quinolinone derivative atypical neuroleptic low EPS/low hyperprolactinemia partial agonist activity at some D...
  166. 166—molindone
    tetrahydroindolone derivative
    atypical neuroleptic
    less potent
    high EPS
    orally active/ rapidly absorbed
    some metabolites are active
    t1/2>24 h    molindone tetrahydroindolone derivative atypical neuroleptic less potent high EPS orally active/ rapidly absorbed some metabolites are ac...
  167. 167—sertindole
    indole derivative
    atypical neuroleptic
    low EPS
    against schizophrenia
    long acting
    non sedating    sertindole indole derivative atypical neuroleptic low EPS against schizophrenia long acting non sedating

Informationen

Beschreibung
Pharmacy Karteikarten am Medchem 1 Final, erstellt von Camille Bassil am 08/12/2017.
Erstellt von
Camille Bassil · Dez 2017
Aktualisiert
16 Dez 2018
Aufrufe
212
Verlauf
  • Erstellt von lola_smily · 28 Dez 2014
  • Kopiert von Camille Bassil · 8 Dez 2017
Bewertung
Durchschnittliche Bewertung 5,0 von 5 (1 Bewertung)

Feedback

Worum geht es?

Wie gefällt dir das neue Design?

Dein Eindruck